Burning Rock Biotech Limited
BNR
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $17.2M
$15.99
▼ -9.30%
P/E
-6.36
Mkt Cap
$17.2M
52-Wk Range
$6.79–$41.72
52-Week Range
$6.79 - $41.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 71.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Hot
+57.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BNR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 17, 2026
SEP 10, 2026
Reported EPS of -$0.20 vs -$2.29 consensus (+91.3% surprise). Revenue of $19.9M vs $19.2M expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+91.3%
Revenue trend · last 1Q
—
Q1 26
$16.0M
Margins · last 1Q
Profit
-16.2%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How BNR stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.